C12N 2710/16611
Simplexvirus
Official title: Simplexvirus, e.g. human herpesvirus 1, 2
C12N2710/16611 (Simplexvirus) appears on 999 US grants and 1,199 published applications in this corpus.
Search patents in C12N- Granted patents
- 999
- Published applications
- 1,199
- Assignees
- 605
- Inventors
- 1,979
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 4 | 0 |
| 1983 | 3 | 0 |
| 1984 | 1 | 0 |
| 1985 | 3 | 0 |
| 1986 | 4 | 0 |
| 1987 | 4 | 0 |
| 1988 | 9 | 0 |
| 1989 | 7 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 11 | 0 |
| 1993 | 12 | 0 |
| 1994 | 11 | 0 |
| 1995 | 7 | 0 |
| 1996 | 21 | 0 |
| 1997 | 32 | 0 |
| 1998 | 59 | 0 |
| 1999 | 41 | 0 |
| 2000 | 44 | 0 |
| 2001 | 41 | 15 |
| 2002 | 34 | 51 |
| 2003 | 39 | 60 |
| 2004 | 29 | 55 |
| 2005 | 19 | 40 |
| 2006 | 25 | 37 |
| 2007 | 20 | 36 |
| 2008 | 20 | 38 |
| 2009 | 19 | 37 |
| 2010 | 24 | 40 |
| 2011 | 20 | 41 |
| 2012 | 25 | 37 |
| 2013 | 18 | 35 |
| 2014 | 35 | 31 |
| 2015 | 19 | 42 |
| 2016 | 18 | 36 |
| 2017 | 34 | 43 |
| 2018 | 27 | 44 |
| 2019 | 44 | 52 |
| 2020 | 37 | 73 |
| 2021 | 27 | 64 |
| 2022 | 39 | 65 |
| 2023 | 18 | 64 |
| 2024 | 32 | 60 |
| 2025 | 33 | 63 |
| 2026 | 22 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16622New viral proteins or individual genes, new structural or functional aspects ofIndexing code544
- C12N 2710/16641Use of virus, viral particle or viral elements as a vectorIndexing code300
- C12N 2710/16634Use of virus or viral component as vaccineIndexing code291
- C12N 2710/16632Use of virus as therapeutic agent, other than vaccineIndexing code159
- C12N 2710/16661Methods of inactivation or attenuationIndexing code112
- C12N 2710/16621Viruses as suchIndexing code90
- C12N 2710/16651Methods of production or purification of viral materialIndexing code63
- C12N 2710/16671Demonstrated in vivo effectIndexing code57
Recent patents
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Stable frozen virus formulation11 Aug 2026US 12,702,688 B2Amgen Inc.
- Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof11 Aug 2026US 12,702,707 B2The Trustees of the University of Pennsylvania
- Treatment using oncolytic virus21 Jul 2026US 12,685,767 B2Replimune Limited
- Oncolytic virus therapy2 Jun 2026US 12,642,832 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Recombinant herpes simplex virus with il-12 expression8 Oct 2026US 2026/0308219 A1
- Metabolic switches for anti-tumor immunity8 Oct 2026US 2026/0308516 A1Cold Spring Harbor Laboratory
- Rna for preventing or treating tuberculosis24 Sep 2026US 2026/0284168 A1
- Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use24 Sep 2026US 2026/0286317 A1The Brigham and Women S Hospital, Inc.
- Use of oncolytic viruses for the treatment of cancer24 Sep 2026US 2026/0286393 A1Amgen Inc.
Most cited
By later US patents
- Modified vaccinia virus298US 4,603,112 AHealth Research, Inc. · 1986
- Modified vaccinia virus and methods for making and using the same264US 4,769,330 AHealth Research, Inc. · 1988
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters186US 5,464,758 A1995
- Methods for regulating gene expression170US 5,814,618 ABASF SE · 1998